Get the Stockscreener App
151.00
1.40%
-2.1018
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Merck Co Inc stock is traded at $151.00, with a volume of 3.91M.
It is down -1.40% in the last 24 hours and up +15.44% over the past month.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
See More
Previous Close:
$153.10
Open:
$149.53
24h Volume:
3.91M
Relative Volume:
0.38
Market Cap:
$372.44B
Revenue:
$65.51B
Net Income/Loss:
$8.93B
P/E Ratio:
42.50
EPS:
3.5532
Net Cash Flow:
$14.12B
1W Performance:
+1.32%
1M Performance:
+15.44%
6M Performance:
+21.91%
1Y Performance:
+79.55%
1-Day Range:
$149.02
$152.08
1-Week Range:
$148.59
$156.92
52-Week Range:
$77.58
$156.92
Merck Co Inc Stock (MRK) Company Profile
Name
Merck Co Inc
Sector
Industry
Phone
908-740-4000
Address
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Compare MRK vs LLY, JNJ, ABBV, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
150.96 | 367.58B | 65.51B | 8.93B | 14.12B | 3.5532 |
LLY
Lilly Eli Co
|
1,186.88 | 1.11T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.00 | 644.33B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
258.49 | 462.68B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
154.87 | 296.97B | 54.66B | 13.58B | 16.05B | 7.0171 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Feb-13-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-08-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Dec-18-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Nov-24-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Oct-13-25 | Resumed | Citigroup | Neutral |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| May-14-25 | Downgrade | Citigroup | Buy → Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-18-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-10-25 | Downgrade | TD Cowen | Buy → Hold |
| Jan-08-25 | Downgrade | Truist | Buy → Hold |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Dec-04-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Peer Perform |
| Nov-11-24 | Downgrade | Daiwa Securities | Buy → Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Mar-11-24 | Downgrade | Societe Generale | Hold → Sell |
| Jan-04-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Buy |
| Oct-27-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Oct-20-23 | Upgrade | UBS | Neutral → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Hold |
| Apr-13-23 | Upgrade | Citigroup | Neutral → Buy |
| Mar-28-23 | Downgrade | Societe Generale | Buy → Hold |
| Mar-13-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Mar-06-23 | Initiated | Jefferies | Buy |
| Feb-22-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-04-23 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Oct-10-22 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-14-22 | Upgrade | Berenberg | Hold → Buy |
| Jul-06-22 | Upgrade | Daiwa Securities | Neutral → Buy |
| Jun-06-22 | Resumed | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Dec-17-21 | Initiated | Goldman | Buy |
| Dec-16-21 | Initiated | Daiwa Securities | Neutral |
| Dec-13-21 | Downgrade | UBS | Buy → Neutral |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Dec-07-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-29-21 | Downgrade | Citigroup | Buy → Neutral |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Nov-01-21 | Upgrade | Argus | Hold → Buy |
| Sep-07-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-27-21 | Resumed | Truist | Buy |
| May-20-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Aug-03-20 | Upgrade | Goldman | Neutral → Buy |
| Jun-12-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Aug-16-19 | Initiated | SVB Leerink | Outperform |
| Jul-03-19 | Initiated | Mizuho | Buy |
| May-28-19 | Initiated | Goldman | Neutral |
| May-13-19 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-16-18 | Reiterated | Citigroup | Buy |
| Oct-09-18 | Resumed | Guggenheim | Buy |
| Apr-23-18 | Upgrade | Goldman | Neutral → Buy |
| Apr-17-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-05-18 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-12-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| Feb-14-18 | Reiterated | Leerink Partners | Mkt Perform |
| Feb-07-18 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-16-18 | Upgrade | SunTrust | Hold → Buy |
View All
Merck Co Inc Stock (MRK) Latest News
The Goldman Sachs Group Forecasts Strong Price Appreciation for Merck & Co., Inc. (NYSE:MRK) Stock - MarketBeat
Strong Merck stock trades close to its 52-week high as analysts lift targets after melanoma trial wi - Ad-hoc-news.de
Merck & Co Inc Stock (MRK) Moved Up by 3.41% on Aug 21: Facts Behind the Movement - TradingKey
Moderna and Merck cancer vaccine success paves way for future - EMJ
TCW Group Inc. Sells 16,921 Shares of Merck & Co., Inc. $MRK - MarketBeat
Summit Global Investments Sells 15,559 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Commonwealth Retirement Investments LLC - MarketBeat
Crew Capital Management Ltd Acquires 7,742 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Acumen Wealth Advisors LLC - MarketBeat
RBC Capital Downgrades Merck & Co as Profit-Taking Sets In - marketscreener.com
Merck & Co. stock hits record high as cancer vaccine data lifts 2026 outlook - Ad-hoc-news.de
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $170.00 - MarketBeat
Merck Raises the Stakes for Pfizer's Cancer Vaccine AmbitionsModerna (NASDAQ:MRNA), Merck & Co (NYSE:M - Benzinga
Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $175.00 - MarketBeat
Merck & Co. stock extends double-digit August rally as analyst calls and cancer vaccine data reshape - Ad-hoc-news.de
RBC Capital downgrades Merck & Co as profit-taking hits the stock - marketscreener.com
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades - Seeking Alpha
Merck & Co., Inc. (NYSE:MRK) Downgraded to "Sector Perform" Rating by Royal Bank Of Canada - MarketBeat
This Merck Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine WinModerna (NASDAQ:MRNA) - Benzinga
Merck & Co., Inc. (NYSE:MRK) Raised to Overweight at Morgan Stanley - MarketBeat
Goldman Sachs Adjusts Price Target on Merck & Co. to $160 From $140, Keeps Buy Rating - Moomoo
Merck & Co., Inc. (NYSE:MRK) Stock Rating Lowered by Jefferies Financial Group - MarketBeat
Morgan Stanley Upgrades Merck & Co. to Overweight From Equalweight, Adjusts PT to $179 From $116 - marketscreener.com
Jennison Associates LLC Has $350.67 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Holdings Trimmed by Hohimer Wealth Management LLC - MarketBeat
Hodges Capital Management Inc. Sells 8,148 Shares of Merck & Co., Inc. $MRK - MarketBeat
Massachusetts Financial Services Co. MA Reduces Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co. stock jumps to record high as cancer vaccine data eases Keytruda risk - Ad-hoc-news.de
MERCK & CO INC : JEFFERIES RAISES TARGET PRICE TO $175 FROM $152 - Moomoo
Why Did MRNA, MRK, TGT Stocks Jump To 52-Week Highs Today? - TradingView
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial GainsPfizer (NYSE:PFE), Mode - Benzinga
Merck & Co Inc : Argus Research Raises Ta - Moomoo
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks TodayModerna (NASDAQ:MRNA) - Benzinga
Shareholders that lost money on Merck & Co., Inc.(MRK) should con - The National Law Review
Why Moderna Stock Skyrocketed Today - The Motley Fool
Moderna and Merck: Intismeran's Positive Phase 3 Readout Confirms mRNA Potential in Oncology - Morningstar
Moderna or Merck: Which Soaring Cancer Vaccine Stock Is the Better Buy? - Finviz
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In FocusMerck & Co (NYSE:MRK) - Benzinga
Merck & Co Inc (MRK) Stock Up 12.6% but GF Value Says Overvalued -- GF Score: 72/100 - GuruFocus
Merck's Large Late-Stage Pipeline Is Building Solid Defense Against Keytruda's Patent Cliff - Morningstar
Pfizer Stock Rises Wednesday: What's Going On? - Benzinga
Stock Traders Buy High Volume of Merck & Co., Inc. Call Options (NYSE:MRK) - MarketBeat
Huge Unusual Put Options Volume in MerckIs MRK Stock Overvalued? - Barchart.com
MERCK CO INC - Financial Post
Merck Soars On Cancer Vaccine Trial Win With Moderna, More Upside Ahead (NYSE:MRK) - Seeking Alpha
Merck: Why Consolidation Looks Like The Next Move (Rating Downgrade) (NYSE:MRK) - Seeking Alpha
Merck stock hits a new 52-week high on melanoma data - Ad-hoc-news.de
Moderna's Cancer Vaccine Win Is Merck's Story Too - Benzinga
Tempus AI Soars as Merck-Moderna Cancer Trial Validates Personalis Acquisition - Benzinga
VIEW Moderna-Merck melanoma vaccine data boosts outlook, but analysts await full results - Reuters
Merck Co Inc Stock (MRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):